• RoundupsRoundups

    FDA Approvals Roundup: Tarpeyo, Dartisla ODT, Yusimry

    A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). New approvals Tarpeyo approved for reducing proteinuria in IgA nephropathy Calliditas Therapeutics’ Tarpeyo (budesonide) delayed release capsules were granted accelerated approval to reduce proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, also known as Berger’s disease, who are at risk of rapid disease progression. Approval of Tarpeyo wa...
  • Regulatory NewsRegulatory News

    FDA removes in-person dispensing requirement for abortion medication

    The US Food and Drug Administration (FDA) is modifying the shared Risk Evaluation and Mitigation Strategy (REMS) for mifepristone products to allow women to continue to access the abortion medication through the mail via a certified prescriber.   The move, highlighted on FDA’s mifepristone information webpage and in updates to an associated question-and-answer (Q&A) page on 16 December, makes permanent the eased restrictions permitted during the COVID-19 pandemic. At...
  • Regulatory NewsRegulatory News

    EC outlines rules for electronic IFU for med devices

    The European Commission has issued rules outlining the circumstances in which medical device instructions for use (IFU) can be provided in electronic form, rather than in paper form.   The implementing regulation , issued on 14 December, brings the European Union into alignment with device regulators in the US, Australia, and other nations, which already allow electronic labeling/IFU for certain medical devices. (RELATED: TGA Offers Guidance on Electronic Instructio...
  • Regulatory NewsRegulatory News

    FDA issues draft guidance on study designs using real-world data

    The US Food and Drug Administration (FDA) has issued draft guidance to industry on how real-world data (RWD) could be used in clinical trials and how it could be incorporated into the design of non-interventional studies.   The draft guidance , released Thursday, outlines the applicability of FDA’s investigational new drug application (IND) regulations to clinical study designs that use RWD and clarifies the agency’s expectations on new drug applications (NDAs) or bio...
  • Regulatory NewsRegulatory News

    Consensus lacking on ‘value’ for new anticancer drugs

    The high price tag of new anticancer drugs has fueled debate about the value of these treatments, given the marginal clinical benefit of some newly approved treatments. But that debate is complicated by a lack of consensus around the definition of value and the different views of stakeholders in cancer care.   In a recent perspectives article in Nature Reviews , authors from the European Medicines Agency (EMA) and the Karolinska Institutet in Sweden explored the diffe...
  • Regulatory NewsRegulatory News

    Experts: Penumbra recall highlights ‘device creep,’ makes case for regulatory reform

    The recent class I recall of a Penumbra cardiac device used in mechanical thrombectomy procedures provides a case study for the shortcomings of the current 510(k) medical device clearance process and the need for more robust device adverse event reporting and postmarketing surveillance, according to a review published in JAMA Internal Medicine .   Penumbra, a California-based medical device company, recalled its JET 7 Reperfusion Catheter with Xtra Flex Technology (JE...
  • Regulatory NewsRegulatory News

    FDA offers draft guidance for registries as RWD

    The US Food and Drug Administration (FDA) released draft guidance on the use of registries in regulatory decision making, adding another piece to the puzzle of how the agency will consider real-world data (RWD) when considering a new drug indication or assessing post-approval requirements.   The draft guidance , which was published Monday, outlines considerations for sponsors and stakeholders when proposing to design a registry or use an existing registry to support r...
  • Regulatory NewsRegulatory News

    FDA shares research to improve dose selection in pediatric drug development

    Dose selection is a significant challenge in pediatric drug development; commonly used renal function equations can overestimate glomerular filtration rates and result in inaccurate predictions of drug elimination.   In a Regulatory Science in Action article , scientists from the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) shared findings about how adjustments to the estimated glomerular filtration rate (eGFR) equations could help ...
  • Regulatory NewsRegulatory News

    GAO: Pathway for antimicrobial drug development leads to few approvals

    A regulatory pathway to encourage development of drugs to combat antimicrobial resistant infections – the limited population pathway for antibacterial and antifungal drugs (LPAD) – has resulted in just two drug approvals by the US Food and Drug Administration (FDA) since 2016, according to a new report from the Government Accountability Office (GAO).   The GAO report , released on 19 November 2021, suggested that the LPAD pathway does not address the underlying econom...
  • Regulatory NewsRegulatory News

    Industry, clinician groups have different wish lists for AI/ML-enabled device labels

    Medical device industry groups are urging the U.S. Food and Drug Administration (FDA) not to rush to create new regulatory requirements around the labeling of medical devices that incorporate artificial intelligence or machine learning (AI/ML), while clinician groups are seeking greater transparency about device algorithms and training data sets.     In total, 15 groups offered comments following a virtual public workshop held by FDA on the transparency of AI/ML-enable...
  • Regulatory NewsRegulatory News

    Friends of Cancer Research urges early dose-finding studies to reduce treatment toxicity

    Friends of Cancer Research is calling on all stakeholders in the cancer community to move away from the idea of “more is better” in drug dosing and begin to incorporate dose-finding studies into the cancer trial process.   Dose optimization is the focus of a new white paper that the group released at its 25 th annual meeting. The paper offers recommendations for performing adequate dose optimization studies in oncology, with a focus on the pre-market setting. “These...
  • Regulatory NewsRegulatory News

    White paper bolsters ctDNA as potential 'early endpoint' in cancer approvals

    A newly released white paper from the Friends of Cancer Research calls for a collaborative effort to investigate the use of circulating tumor DNA (ctDNA) as an “early endpoint” to predict long-term cancer survival outcomes in early-stage cancers.   This type of early endpoint could be used by regulators when considering certain accelerated cancer approvals. But the group acknowledged that more robust data is needed, as well as harmonization around definitions and stand...